Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · NATCOPHARM

NATCO PHARM

HealthcarePharmaceuticals & Biotechnology₹16094 cr market cap
₹806.65 ▼ -1.7% today As of 19 Nov 2026
52-week low ₹781.6052-week high ₹1206.00

-32.0% from the 52-week high · +5.0% above the low

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

The short version. NATCO PHARM reported revenue of ₹967 crore for Sep 2026, down 29.1% from a year earlier. Net profit was ₹203 crore (down 60.8% year on year). Return on equity was 15.4% in Mar 2026. Promoter holding was 49.39% in Sep 2026, down 0.23 points over 8 quarters.

1 · The price

How has the stock traded?

NATCO PHARM trades 32.0% below its 52-week high and 5.0% above its 52-week low.

Change over period: —

1M+2.5%
3M-7.5%
6M-29.0%
1Y+0.7%

2 · The business

Is it growing?

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue967735739647136313291221475
Net profit203206268152518481407133
Net margin %20.928.136.223.438.036.233.328.0
EPS (₹)10.3310.5313.667.7226.4324.520.736.78

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue40784430399927071945205219152094
Net profit141818851388715170441461644
Net margin %34.842.634.726.48.721.524.130.8
EPS (₹)72.3196.1170.7735.798.522.0823.1132.17

3 · The quality

How well does it turn capital into profit?

Return on equity was 15.4% in Mar 2026; debt to equity is 0.08.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %15.424.823.714.7
Return on capital %16.330.128.517.6
EBITDA margin %39.653.345.537.0
Net margin %32.439.433.625.4

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR15.9%15.2%
Profit CAGR25.6%26.3%
Debt to equity0.08
Interest cover41.6x
Current ratio3.01
P/E ratio17.9

4 · The owners

Who holds it, and are they adding?

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter49.6249.5649.5649.4849.4849.4149.4149.39-0.23
FII17.9417.4915.5114.0915.1617.3716.9916.0-1.94
DII5.575.655.825.875.395.465.626.16+0.59
Public26.8727.2929.1130.5629.9627.7527.9728.45+1.58

Mutual fund holdings · Oct 2026

105 schemes hold this stock

69 the month before.

  • ICICI Prudential Contra Fund6.59% of NAV
  • TATA INDIA PHARMA & HEALTHCARE FUND2.86% of NAV
  • Bank of India Value Fund2.18% of NAV
  • TATA SMALL CAP FUND1.72% of NAV
  • DSP Nifty Smallcap250 Quality 50 Index Fund1.65% of NAV
  • Sundaram Long Term Tax Advantage Fund Series IV1.63% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series VI1.61% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series IV1.6% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for NATCO PHARM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Corporate actions

Recent dividends, bonuses and splits

  • 18 Feb 2026 · Interim Dividend - Rs. 1.5
  • 20 Nov 2025 · Interim Dividend - Rs. 1.5
  • 19 Aug 2025 · Interim Dividend - Rs. 2
  • 18 Feb 2025 · Interim Dividend - Rs. 1.5
  • 27 Nov 2024 · Interim Dividend - Rs. 1.5
  • 23 Aug 2024 · Interim Dividend - Rs. 3

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.